EP 4236963 A1 20230906 - 5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO]-CHOLESTAN-3BETA-OL ANALOGUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER
Title (en)
5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO]-CHOLESTAN-3BETA-OL ANALOGUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER
Title (de)
5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO CHOLESTAN-3BETA-OL ANALOGE UND DIESE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON KREBS
Title (fr)
ANALOGUES DU 5ALPHA-HYDROXY-6 BETA-[2-(1-H-IMIDAZOL-4-YL)ETHYLAMINO]-CHOLESTAN-3 BETA-OL ET COMPOSITIONS PHARMACEUTIQUES LE COMPRENANT POUR UTILISATION DANS LE TRAITEMENT DU CANCER
Publication
Application
Priority
- BE 202005764 A 20201029
- BE 202005878 A 20201203
- EP 2021080054 W 20211028
Abstract (en)
[origin: WO2022090427A1] The present invention relates to a novel compound of general formula (I), and/or a pharmaceutically acceptable salt of such a compound, a pharmaceutical composition comprising at least said compound, for use as a drug for shrinking cancerous tumours in mammals.
IPC 8 full level
A61K 31/575 (2006.01); A61K 31/24 (2006.01); A61K 31/36 (2006.01); A61K 31/58 (2006.01); A61K 31/704 (2006.01); A61K 33/24 (2019.01); A61K 33/36 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01)
CPC (source: EP KR US)
A61K 31/24 (2013.01 - EP); A61K 31/36 (2013.01 - EP); A61K 31/575 (2013.01 - EP); A61K 31/58 (2013.01 - EP KR); A61K 31/704 (2013.01 - EP); A61K 45/06 (2013.01 - EP US); A61P 35/00 (2017.12 - EP KR); A61P 35/02 (2017.12 - EP KR US); C07J 43/003 (2013.01 - US)
Citation (search report)
See references of WO 2022090427A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2022090427 A1 20220505; AU 2021372797 A1 20230615; AU 2021372797 A2 20230629; CA 3196518 A1 20220505; EP 4236963 A1 20230906; JP 2023551363 A 20231208; KR 20230097077 A 20230630; US 2023391817 A1 20231207
DOCDB simple family (application)
EP 2021080054 W 20211028; AU 2021372797 A 20211028; CA 3196518 A 20211028; EP 21801547 A 20211028; JP 2023526224 A 20211028; KR 20237017165 A 20211028; US 202118034317 A 20211028